About Famy Life Sciences Private Limited
Data last updated: 07 January 2026
Famy Life Sciences Private Limited is a private limited company based in Shaikpet, Telangana, India. It specialises in wholesale trading and distribution, a part of the broader trading and commerce sector. Incorporated on 27 October 2008, the company has been in operation for over 18 years.
Registered with ROC Hyderabad under CIN U40109GJ2008PTC109640.
Capital: an authorised share capital of ₹1.51 Cr and a paid-up capital of ₹1.42 Cr. Formerly known as Famy Energy Private Limited. It is led by directors Ajay Singh Rathore and Nagaraj Goud Bodige.
Last AGM: 30 September 2025. Financial statements filed for year ended 31 March 2025. Office: Plot No. 564/A/22 Road No. 92, Telangana.
As per the financials filed for FY 2025, the company reported a revenue of ₹2.36 Cr, a growth of 9% compared to the previous year.
The company has a workforce of approximately 8 employees as per the latest available data.
The company is associated with 1 brand - Famy Life Sciences. As per MCA filings, the company has satisfied charges of ₹110 Cr on record.
The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website famylifesciences.com.
-
Email*****@*****.com
-
Telephone**************
-
Website
-
Social Media**************
-
Registered AddressPlot No. 564/A/22 Road No. 92, Hyderabad Telangana 500096, Shaikpet, Telangana, India – 500096
-
IndustryTrading, Wholesale, Other Wholesale
- Historical Financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Litigation, compliance and MCA filings
- PDF report delivered after checkout
CIN History of Famy Life Sciences Private Limited
Famy Life Sciences Private Limited has 2 previous CINs, indicating changes in the company's corporate structure or registration details. The current CIN is U40109TS2008PTC188720, which is the unique identifier assigned by the Registrar of Companies.
| CIN | Status |
|---|---|
| U40109TS2008PTC188720 | Current |
| U40109GJ2008PTC109640 | Previous |
| U40109MH2008PTC187793 | Previous |
Associated Brands with Famy Life Sciences Private Limited
Famy Life Sciences Private Limited operates one associated brand: Famy Life Sciences. These brands represent Famy Life Sciences Private Limited's diversified market presence and brand portfolio.
| Brand | Description | Website |
|---|---|---|
| Drug development services are offered for ophthalmology, oncology, and dermatology. | famylifesciences.com |
Competitors & Alternatives of Famy Life Sciences Private Limited
Brands and companies operating in the same space as Famy Life Sciences Private Limited include Nephron Pharmaceuticals, Suanfarma, Enzene Biosciences and 5 more.
| Competitor | Description | Location | Founded |
|---|---|---|---|
Nephron Pharmaceuticals
|
Sterile pharmaceutical products are manufactured and contract services are provided. | Florida, Puerto Rico, United States | 1937 |
Suanfarma
|
Generics, nutraceuticals, and APIs are developed by Suanfarma. | Madrid, Spain, Spain | 1993 |
Enzene Biosciences
|
Company specializing in development of Biosimilars | Pune, India, India | 2006 |
Quotient Sciences
|
APIs and finished dosage forms are developed and manufactured. | Nottingham, United Kingdom, United Kingdom | 1990 |
Hybio Pharmaceutical
|
Polypeptide drugs and APIs are developed and manufactured. | Shenzhen, China, China | 1998 |
Aiolos Bio
|
Biotech company focused on developing innovative therapies for respiratory diseases and immune conditions | Boston, United States, United States | 2023 |
Kardigan
|
Biotech company developing personalized medicines for cardiovascular diseases | San Francisco, United States, United States | 2023 |
AmbioPharm
|
CDMO and analytical services for peptide development are provided. | North Augusta, United States, United States | 2006 |
Business Activity of Famy Life Sciences Private Limited
Famy Life Sciences Private Limited is engaged in the principal business activity of trade, with detailed activities including wholesale trading.
| Main Activity Group Code | Description of Main Activity | Business Activity Code | Description of Business Activity | Turnover Percentage |
|---|---|---|---|---|
| G | Trade | G1 | Wholesale Trading | ********* |
Auditor Details of Famy Life Sciences Private Limited
Famy Life Sciences Private Limited is audited by S M M P & COMPANY for the financial year 2022. The auditor plays a crucial role in ensuring financial transparency and compliance with accounting standards.
| Name | Status | Appointment Date | Cessation Date |
|---|---|---|---|
| S M M P & COMPANY | blur-value | blur-value | blur-value |
Board of Directors of Famy Life Sciences Private Limited
Famy Life Sciences Private Limited is currently managed by 2 directors, with 12 former directors having served the organization. The current Directors play a crucial role in shaping the company's strategic direction and governance.
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
|
Ajay Singh Rathore
Also directs:
Mylan Pharmaceuticals Private Limited
|
Director | 10 Feb 2023 | 3 Years 4 Months | Current |
|
Nagaraj Goud Bodige
Also directs:
Mylan Laboratories Limited
|
Director | 13 Mar 2025 | 1 Years 3 Months | Current |
Financials of Famy Life Sciences Private Limited FY 2025 filings available
Famy Life Sciences Private Limited reported revenue of ₹2.36 Cr (up 9% YoY) for FY 2025. Profit growth despite declining revenue indicates effective cost management and margin discipline.
| Metrics | ***** | ***** | ***** | ***** | ***** |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue from Operations | ***** | ***** | ***** | ***** | ***** |
| Revenue Growth % | ***** | ***** | ***** | ***** | ***** |
| Other Income | ***** | ***** | ***** | ***** | ***** |
| Total Revenue | ***** | ***** | ***** | ***** | ***** |
| Expenses | |||||
| Total Expenses | ***** | ***** | ***** | ***** | ***** |
| Raw Material Cost | ***** | ***** | ***** | ***** | ***** |
| Change in Inventory FG | ***** | ***** | ***** | ***** | ***** |
| Change in Inventory WIP | ***** | ***** | ***** | ***** | ***** |
| Purchase of Traded Goods | ***** | ***** | ***** | ***** | ***** |
| Employee Cost | ***** | ***** | ***** | ***** | ***** |
| Managerial Remuneration | ***** | ***** | ***** | ***** | ***** |
| Audit Fees | ***** | ***** | ***** | ***** | ***** |
| Insurance | ***** | ***** | ***** | ***** | ***** |
| Power & Fuel | ***** | ***** | ***** | ***** | ***** |
| Interest | ***** | ***** | ***** | ***** | ***** |
| Depreciation | ***** | ***** | ***** | ***** | ***** |
| Other Expenses | ***** | ***** | ***** | ***** | ***** |
| Profitability | |||||
| EBITDA (Operating Profit) | ***** | ***** | ***** | ***** | ***** |
| Operating Margin % | ***** | ***** | ***** | ***** | ***** |
| Exceptional Items | ***** | ***** | ***** | ***** | ***** |
| Extraordinary Items | ***** | ***** | ***** | ***** | ***** |
| Profit Before Exceptional & Extraordinary Items | ***** | ***** | ***** | ***** | ***** |
| Profit Before Tax | ***** | ***** | ***** | ***** | ***** |
| Tax & Net Profit | |||||
| Tax Expense | ***** | ***** | ***** | ***** | ***** |
| Current Tax | ***** | ***** | ***** | ***** | ***** |
| Deferred Tax | ***** | ***** | ***** | ***** | ***** |
| Profit from Discontinued Operations | ***** | ***** | ***** | ***** | ***** |
| Tax on Discontinued Operations | ***** | ***** | ***** | ***** | ***** |
| Profit | ***** | ***** | ***** | ***** | ***** |
| Net Margin % | ***** | ***** | ***** | ***** | ***** |
| Metrics | ***** | ***** | ***** | ***** | ***** |
|---|---|---|---|---|---|
| Shareholders' Funds | |||||
| Total Shareholders' Funds | ***** | ***** | ***** | ***** | ***** |
| Equity Capital | ***** | ***** | ***** | ***** | ***** |
| Reserves & Surplus | ***** | ***** | ***** | ***** | ***** |
| Money Against Warrants | ***** | ***** | ***** | ***** | ***** |
| Other Equity | ***** | ***** | ***** | ***** | ***** |
| Non-Current Liabilities | |||||
| Total Non-Current Liabilities | ***** | ***** | ***** | ***** | ***** |
| Long-Term Borrowings | ***** | ***** | ***** | ***** | ***** |
| Deferred Tax Liabilities | ***** | ***** | ***** | ***** | ***** |
| Other Non-Current Liabilities | ***** | ***** | ***** | ***** | ***** |
| Long-Term Provisions | ***** | ***** | ***** | ***** | ***** |
| Current Liabilities | |||||
| Total Current Liabilities | ***** | ***** | ***** | ***** | ***** |
| Short-Term Borrowings | ***** | ***** | ***** | ***** | ***** |
| Trade Payables | ***** | ***** | ***** | ***** | ***** |
| Other Current Liabilities | ***** | ***** | ***** | ***** | ***** |
| Short-Term Provisions | ***** | ***** | ***** | ***** | ***** |
| Total Equity & Liabilities | ***** | ***** | ***** | ***** | ***** |
| Non-Current Assets | |||||
| Non-Current Assets | ***** | ***** | ***** | ***** | ***** |
| Tangible Assets | ***** | ***** | ***** | ***** | ***** |
| Intangible Assets | ***** | ***** | ***** | ***** | ***** |
| Capital WIP | ***** | ***** | ***** | ***** | ***** |
| Intangibles Under Dev | ***** | ***** | ***** | ***** | ***** |
| Investments | ***** | ***** | ***** | ***** | ***** |
| Deferred Tax Assets | ***** | ***** | ***** | ***** | ***** |
| LT Loans & Advances | ***** | ***** | ***** | ***** | ***** |
| Other Non-Current Assets | ***** | ***** | ***** | ***** | ***** |
| Current Assets | |||||
| Current Assets | ***** | ***** | ***** | ***** | ***** |
| Current Investments | ***** | ***** | ***** | ***** | ***** |
| Inventories | ***** | ***** | ***** | ***** | ***** |
| Trade Receivables | ***** | ***** | ***** | ***** | ***** |
| Cash & Bank Balance | ***** | ***** | ***** | ***** | ***** |
| ST Loans & Advances | ***** | ***** | ***** | ***** | ***** |
| Other Current Assets | ***** | ***** | ***** | ***** | ***** |
| Total Assets | ***** | ***** | ***** | ***** | ***** |
| Metrics | ***** | ***** | ***** | ***** | ***** |
|---|---|---|---|---|---|
| Cash from Operating Activities (CFO) | |||||
| Profit Before Tax | ***** | ***** | ***** | ***** | ***** |
| Non-Cash Adjustments | ***** | ***** | ***** | ***** | ***** |
| + Interest Expense | ***** | ***** | ***** | ***** | ***** |
| + Depreciation | ***** | ***** | ***** | ***** | ***** |
| +/- Unrealized Forex | ***** | ***** | ***** | ***** | ***** |
| - Dividend Income | ***** | ***** | ***** | ***** | ***** |
| - Interest Income | ***** | ***** | ***** | ***** | ***** |
| +/- Other Non-Cash Items | ***** | ***** | ***** | ***** | ***** |
| Changes in Working Capital | ***** | ***** | ***** | ***** | ***** |
| +/- Inventory | ***** | ***** | ***** | ***** | ***** |
| +/- Debtors | ***** | ***** | ***** | ***** | ***** |
| +/- Creditors | ***** | ***** | ***** | ***** | ***** |
| Reconciliation Adjustments | ***** | ***** | ***** | ***** | ***** |
| Cash Generated from Operations | ***** | ***** | ***** | ***** | ***** |
| Income Taxes Paid | ***** | ***** | ***** | ***** | ***** |
| Net CFO (Cash from Operations) | ***** | ***** | ***** | ***** | ***** |
| Cash from Investing Activities (CFI) | |||||
| Acquisitions & Disposals | ***** | ***** | ***** | ***** | ***** |
| Disposal of Subsidiaries | ***** | ***** | ***** | ***** | ***** |
| Acquisition of Subsidiaries | ***** | ***** | ***** | ***** | ***** |
| Capex | ***** | ***** | ***** | ***** | ***** |
| Purchase of Fixed Assets | ***** | ***** | ***** | ***** | ***** |
| Sale of Fixed Assets | ***** | ***** | ***** | ***** | ***** |
| Other Investing Cash Flows | ***** | ***** | ***** | ***** | ***** |
| Net CFI (Cash from Investing) | ***** | ***** | ***** | ***** | ***** |
| Cash from Financing Activities (CFF) | |||||
| Equity Issuance | ***** | ***** | ***** | ***** | ***** |
| Debt Raised | ***** | ***** | ***** | ***** | ***** |
| Debt Repaid | ***** | ***** | ***** | ***** | ***** |
| Dividends Paid | ***** | ***** | ***** | ***** | ***** |
| Interest Paid | ***** | ***** | ***** | ***** | ***** |
| Net CFF (Cash from Financing) | ***** | ***** | ***** | ***** | ***** |
| Net Cash Position | |||||
| Net Change in Cash (Pre-Forex) | ***** | ***** | ***** | ***** | ***** |
| Closing Cash & Equivalents | ***** | ***** | ***** | ***** | ***** |
| Metrics | ***** | ***** | ***** | ***** | ***** |
|---|---|---|---|---|---|
| Liquidity | |||||
| Current Ratio | ***** | ***** | ***** | ***** | ***** |
| Quick Ratio | ***** | ***** | ***** | ***** | ***** |
| Cash Ratio | ***** | ***** | ***** | ***** | ***** |
| Efficiency | |||||
| Inventory Days | ***** | ***** | ***** | ***** | ***** |
| Debtor Days | ***** | ***** | ***** | ***** | ***** |
| Creditor Days | ***** | ***** | ***** | ***** | ***** |
| Cash Conversion Cycle | ***** | ***** | ***** | ***** | ***** |
| Asset Turnover | ***** | ***** | ***** | ***** | ***** |
| Profitability | |||||
| Net Profit Margin % | ***** | ***** | ***** | ***** | ***** |
| Operating Margin % | ***** | ***** | ***** | ***** | ***** |
| ROE % | ***** | ***** | ***** | ***** | ***** |
| ROCE % | ***** | ***** | ***** | ***** | ***** |
| Net Worth Margin % | ***** | ***** | ***** | ***** | ***** |
| Growth | |||||
| Revenue Growth % | ***** | ***** | ***** | ***** | ***** |
| Leverage | |||||
| Equity Multiplier | ***** | ***** | ***** | ***** | ***** |
| Debt / EBITDA | ***** | ***** | ***** | ***** | ***** |
| Solvency | |||||
| D/E Ratio | ***** | ***** | ***** | ***** | ***** |
| ICR | ***** | ***** | ***** | ***** | ***** |
Consolidated Statements
Income Statement, Balance Sheet, Cash Flow & Ratios available in the full report.
Shareholding Pattern of Famy Life Sciences Private Limited
As of FY 2022, Famy Life Sciences Private Limited's shareholding pattern shows 83.54% by promoters, 16.47% by public shareholders. The promoters hold a majority stake, indicating strong promoter control.
| Year | 2025 |
|---|---|
| Promoters | 33.19% |
| DII | 23.22% |
| FII | 18.28% |
| Public | 22.89% |
| Others | 2.42% |
Charges & Borrowings of Famy Life Sciences Private Limited
| Date | Lender | Amount | Status |
|---|---|---|---|
| 14 Aug 2017 | Others | ₹100 Cr | Satisfied |
| 03 Jan 2011 | Hdfc Bank Limited | ₹10 Cr | Satisfied |
Total charge records: 2 View all charges
Employees and EPFO Compliance at Famy Life Sciences Private Limited
Famy Life Sciences Private Limited has a workforce of 8 employees as of Mar 27, 2024.
Employee Count & EPFO Data of Famy Life Sciences Private Limited
Access employee headcount trends, monthly PF payment records, EPFO establishment details, and compliance data.
GST Compliance of Famy Life Sciences Private Limited
GSTIN & GST Filing Data of Famy Life Sciences Private Limited
Access GSTIN registrations, state-wise filing compliance, HSN/SAC codes, and detailed goods & services data.
Credit Ratings, Litigation & Regulatory Alerts for Famy Life Sciences Private Limited
Credit Ratings, Legal Cases & Regulatory Alerts of Famy Life Sciences Private Limited
Access complete credit rating history, litigation records, regulatory alerts, and compliance data.
MSME Payment Delays by Famy Life Sciences Private Limited
MSME Payment Delays by Famy Life Sciences Private Limited
Track payments outstanding to micro and small enterprise vendors, as disclosed in half-yearly MSME-1 returns filed with the MCA.
Subsidiaries & Group Companies of Famy Life Sciences Private Limited
Subsidiaries & Group Companies of Famy Life Sciences Private Limited
See the full corporate group - holding company, subsidiaries, associates and joint ventures of Famy Life Sciences Private Limited with ownership details.
MCA Filings & Documents of Famy Life Sciences Private Limited
MCA Filings & Documents of Famy Life Sciences Private Limited
Download official documents filed with the Ministry of Corporate Affairs - from incorporation papers to the latest annual filings.
Recent Activity on Famy Life Sciences Private Limited
Frequently Asked Questions about Famy Life Sciences Private Limited
Famy Life Sciences Private Limited is an active private limited company in the trading sector based in Shaikpet, Telangana, India. It was incorporated on 27 October 2008 (18+ years old) and is registered under CIN U40109TS2008PTC188720. The company has 8 employees.
Famy Life Sciences Private Limited reported revenue of ₹2.36 Cr for FY 2025 (up 9.00% YoY).
The current directors of Famy Life Sciences Private Limited are:
The primary industry of Famy Life Sciences Private Limited is trading. The company specifically operates in wholesale. The company is currently active in this sector.
Famy Life Sciences Private Limited can be reached at the registered office: Plot No. 564A22 Road No. 92, Hyderabad Telangana 500096, Shaikpet, Telangana, India – 500096, or through the website famylifesciences.com.
The authorised capital is ₹1.51 Cr, and the paid-up capital is ₹1.42 Cr.